Pacer Advisors
ALLO icon

Pacer Advisors’s Allogene Therapeutics ALLO Stock Holding History

Pacer Advisors’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,372
Closed -$5.53K – 2560
2024
Q2 		$5.53K Sell
2,372
-1,285
-35% -$3.79K ﹤0.01% 3627
2024
Q1 		$16.3K Buy
+3,657
New +$15.3K ﹤0.01% 3478
2021
Q2 		– Sell
-2,028
Closed -$72K – 1408
2021
Q1 		$72K Sell
2,028
-2,802
-58% -$94.5K ﹤0.01% 1358
2020
Q4 		$122K Buy
4,830
+2,318
+92% +$75.6K ﹤0.01% 1333
2020
Q3 		$95K Buy
+2,512
New +$94.7K ﹤0.01% 1254

Other funds holding ALLO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Pacer Advisors's ALLO Position: Q3 2024 in Review

Pacer Advisors sold out of Allogene Therapeutics (ALLO) in Q3 2024, closing a stake of 2,372 shares — an estimated $5.53K sold.

Pacer Advisors first reported a position in ALLO in Q3 2020 and held it in 5 quarters. The position peaked at $122K in Q4 2020. 156 funds tracked by Wall St. Rank hold ALLO as of Q3 2024.

  • Pacer Advisors reported no remaining Allogene Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Pacer Advisors sold 2,372 Allogene Therapeutics shares in Q3 2024, an estimated $5.53K.
  • Pacer Advisors first reported a position in Allogene Therapeutics in Q3 2020 and held it in 5 quarters.
  • Pacer Advisors's Allogene Therapeutics position peaked at $122K in Q4 2020.
  • 156 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2024.

Based on Pacer Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.